Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56734 | 0.86 | MAPK1 (0.44) | ALDH1A1MAPTCYP1A2KMT2AMAPK1 | |
| SCHEMBL9316251 | 0.83 | TSHR (0.35) | KIF11ALDH1A1KMT2AMEN1 | |
| SCHEMBL10806930 | 0.75 | KIF11 (0.52) | KIF11CYP2C9PTPN5ALDH1A1MAPT | |
| SCHEMBL128222 | 0.74 | KIF11 (0.59) | KIF11CYP2C9PTPN5ALDH1A1RXRA | |
| SCHEMBL15832876 | 0.74 | ALDH1A1 (0.58) | KIF11CYP2C9PTPN5ALDH1A1CYP1A2 | |
| SCHEMBL3421942 | 0.74 | KIF11 (0.59) | KIF11CYP2C9PTPN5ALDH1A1RXRA | |
| SCHEMBL9461 | 0.74 | MAPK1 (0.43) | KIF11CYP2C9PTPN5ALDH1A1MAPT | |
| SCHEMBL8916291 | 0.74 | KIF11 (0.42) | KIF11CYP2C9PTPN5MAPTSMN1; SMN2 | |
| SCHEMBL6209830 | 0.73 | KMT2A (0.50) | MAPTSMN1; SMN2CYP1A2KMT2AMEN1 | |
| SCHEMBL18396557 | 0.73 | RAB9A (0.41) | ALDH1A1MAPTSMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12011425-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-11760755-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11738019-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-08-03 | — | — | US | disclosed |
| US-11596611-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| EP-3426245-B1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11236111-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210283077-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2021-09-16 | — | — | US | disclosed |
| US-20210230176-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2021-07-29 | — | — | US | disclosed |
| US-11058678-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20090053175-A1 | SUBSTITUTE PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090047247-A1 | Pyrrolidine Derivatives | ENANTA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090022689-A1 | C4-SPIRO-PYRROLIDINE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090004140-A1 | 4-SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES | ENANTA PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| WO-2009003009-A1 | SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008061189-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2007044927-A2 | 6, 11-BRIDGED TRICYCLIC MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| EP-0001449-B1 | ANALOGUES OF SOMATOSTATIN, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PREPARATION | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230176-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | KIF11 4315/4885CYP2C9 462/4885PTPN5 557/4885 |
| US-11236111-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | KIF11 3074/4885CYP2C9 685/4885PTPN5 1220/4885 |
| US-11596611-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | KIF11 4315/4885CYP2C9 462/4885PTPN5 557/4885 |
| US-11760755-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | KIF11 3074/4885CYP2C9 685/4885PTPN5 1220/4885 |
| US-20090004140-A1 | 4-SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES | EIF2AK2, RNGTT, POLR2E | KIF11 3942/4885CYP2C9 280/4885PTPN5 701/4885 |
| US-20090022689-A1 | C4-SPIRO-PYRROLIDINE ANTIVIRALS | ZC3HAV1, HAVCR2, HCCS | KIF11 3569/4885CYP2C9 597/4885PTPN5 885/4885 |
| US-20090053175-A1 | SUBSTITUTE PYRROLIDINE DERIVATIVES | POLRMT, EIF2AK2, NSUN2 | KIF11 3831/4885CYP2C9 511/4885PTPN5 588/4885 |
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | KIF11 4315/4885CYP2C9 462/4885PTPN5 557/4885 |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | CYP2C9, CCR9, DPP9 | KIF11 3795/4885CYP2C9 1/4885PTPN5 1465/4885 |
| US-12011425-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | KIF11 4315/4885CYP2C9 462/4885PTPN5 557/4885 |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | CYP2B6, CYP2D6, ABCB11 | KIF11 1122/4885CYP2C9 10/4885PTPN5 1653/4885 |
| US-11058678-B2 | Substituted heterocycles as antiviral agents | HCCS, HDGF, HAVCR2 | KIF11 4285/4885CYP2C9 243/4885PTPN5 1169/4885 |
| US-20210283077-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | KIF11 4315/4885CYP2C9 462/4885PTPN5 557/4885 |
| US-11738019-B2 | Substituted heterocycles as antiviral agents | HCCS, HDGF, HAVCR2 | KIF11 4285/4885CYP2C9 243/4885PTPN5 1169/4885 |
| US-20090047247-A1 | Pyrrolidine Derivatives | ZC3HAV1, EIF2AK2, POLRMT | KIF11 3590/4885CYP2C9 530/4885PTPN5 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.